Past, Present, and Future of Augmentation of Monocyte Function in the Surgical Patient

Surgical Infections

Volumn 17, Issue 5, 2016, Pages 563-569

  Galbraith, Norman ^a   Walker, Samuel ^a   Carter, Jane ^a   Polk, Hiram C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; CELL FUNCTION; DRUG USE; HUMAN; IMMUNE RESPONSE; MONOCYTE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURGICAL PATIENT; TREATMENT INDICATION; DRUG EFFECTS; IMMUNOLOGY; PHYSIOLOGY; SEPSIS; SURGERY;

ADJUVANTS, IMMUNOLOGIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-GAMMA; MONOCYTES; SEPSIS; SURGICAL PROCEDURES, OPERATIVE;

EID: 84988985718     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2016.014     Document Type: Article

References (36)

1. Galbraith NJ, Walker SP, Gardner SA, Polk HC Jr. The significance and challenges of monocyte impairment: For the ill patient and the surgeon. Surg Infect 2016;17:303-312.
2. Docke WD, Hoflich C, Davis KA, et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: A multicenter standardized study. Clin Chem 2005;51:2341-2347.
3. Demaret J, Walencik A, Jacob MC, et al. Inter-laboratory assessment of flow cytometric monocyte HLA-DR ex-pression in clinical samples. Cytomet Part B: Clin Cytomet 2013;84(1):59-62.
4. Dries DJ, Jurkovich GJ, Maier RV, et al. Effect of interferon gamma on infection-related death in patients with severe injuries: A randomized, double-blind, placebo-controlled trial. Arch Surg 1994;129:1031-1042.
5. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat Med 1997;3:678-681.
6. Polk HC Jr, Cheadle WG, Livingston DH, et al. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 1992;163:191-196.
7. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: New mechanisms, molecules and clinical significance. Trends Immunol 2009;30:475-487.
8. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: Endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006;10:233.
9. Turina M, Dickinson A, Gardner S, Polk HC Jr. Monocyte HLA-DR and interferon-gamma treatment in severely injured patients: A critical reappraisal more than a decade later. J Am Coll Surg 2006;203:73-81.
10. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
11. Wasserman D, Ioannovich JD, Hinzmann RD, et al. Interferon-gamma in the prevention of severe burn-related infections: A European Phase III multicenter trial. The Severe Burns Study Group. Crit Care Med 1998;26:434-439.
12. Nakos G, Malamou-Mitsi VD, Lachana A, et al. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med 2002:30:1488-1494.
13. Schinkel C, Licht K, Zedler S, et al. Perioperative treatment with human recombinant interferon-gamma: A randomized double-blind clinical trial. Shock 2001;16:329-333.
14. Licht AK, Schinkel C, Zedler S, et al. Effects of perioperative recombinant human IFN-gamma (rHuIFN-gamma) application in vivo on T cell response. J Interferon Cytokine Res 2003;23:149-154.
15. Meisel C, Schefold JC, Pschowski R, et al. Granulocytemacrophage colony-stimulating factor to reverse sepsisassociated immunosuppression:Adouble-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-648.
16. Leentjens J, Kox M, Koch RM, et al. Reversal of immunoparalysis in humans in vivo: A double-blind, placebocontrolled, randomized pilot study. Am J Respir Crit Care Med 2012;186:838-845.
17. Spies C, Luetz A, Lachmann G, et al. Influence of granulocyte-macrophage colony-stimulating factor or influenza vaccination on HLA-DR, infection and delirium days in immunosuppressed surgical patients: Double blind, randomised controlled trial. PloS One 2015;10:e0144003.
18. Schneider C, von Aulock S, Zedler S, et al. Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 2004;239:75-81.
19. Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: A meta-analysis. Crit Care 2011;15:R58.
20. Cheadle WG, Hanasawa K, Gallinaro RN, et al. Endotoxin filtration and immune stimulation improve survival from gram-negative sepsis. Surgery 1991;110:785-791.
21. Esteban E, Ferrer R, Alsina L, Artigas A. Immunomodulation in sepsis: The role of endotoxin removal by polymyxin B-immobilized cartridge. Mediators Inflamm 2013; 2013:507-539.
22. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-2064.
23. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med 2014;20:195-203.
24. Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial.JAMA2013;309:1154-1162.
25. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: A novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013;13:260-268.
26. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862-874.
27. Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. IntensCare Med 2006;32:1175-1183.
28. Venet F, Tissot S, Debard AL, et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock. Crit Care Med 2007;35:1910-1917.
29. Zhou J, Chaudhry H, Zhong Y, et al. Dysregulation in microRNA expression in peripheral blood mononuclear cells of sepsis patients is associated with immunopathology. Cytokine 2015;71:89-100.
30. Wang HJ, Zhang PJ, Chen WJ, et al. Characterization and identification of novel serum microRNAs in sepsis patients with different outcomes. Shock 2013;39:480-487.
31. Wang H, Zhang P, Chen W, et al. Serum microRNA signatures identified by Solexa sequencing predict sepsis patients' mortality: A prospective observational study. PloS One 2012;7:e38885.
32. Wang HJ, Zhang PJ, ChenWJ, et al. Four serum microRNAs identified as diagnostic biomarkers of sepsis. J Trauma Acute Care Surg 2012;73:850-854.
33. Uhlich RM, Konie JA, Davis JW, et al. Novel microRNA correlations in the severely injured. Surgery 2014;156:834-840.
34. Owen HC, Torrance HD, Jones TF, et al. Epigenetic regulatory pathways involving microRNAs may modulate the host immune response following major trauma. J Trauma Acute Care Surg 2015;79:766-772.
35. Zhang AQ, Gu W, Zeng L, et al. Genetic variants of microRNA sequences and susceptibility to sepsis in patients with major blunt trauma. Ann Surg 2015;261:189-196.
36. Tacke F, Roderburg C, Benz F, et al. Levels of circulating miR-133a are elevated in sepsis and predict mortality in critically ill patients. Crit Care Med 2014;42:1096-1104.